Imaging Study for Early Detection of Heart Failure With Preserved Ejection Fraction
Uses several heart scans to study and detect early heart changes in people with HFpEF.
Plain-language title generated from the registry record
Registry title: Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with heart failure whose heart still pumps normally (preserved ejection fraction), with signs of heart failure and changes in heart structure or function on scans.
- Sex
- All sexes can join.
- Disease stage
- Heart failure with preserved ejection fraction (LVEF 50% or higher), with symptoms and signs of heart failure, and at least one abnormal finding in heart structure (thickened left ventricle or enlarged left atrium) and function (on Doppler ultrasound).
- Biomarker or test result
- NT-proBNP above 220pg/ml, or BNP above 80 pg/ml.
Main reasons for not taking part
- Special types of heart muscle disease, such as hypertrophic or restrictive cardiomyopathy
- Heart attack, or heart muscle scarring from ischemic cardiomyopathy or acute coronary syndrome
- Severe arrhythmia
- Severe primary heart valve disease
- Restrictive pericardial disease
Read by machine on 12 November 2026.
Where in China
- Fuwai HospitalBeijing, ChinaContact: Minjie Lu, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT04602338
- Record updated
- 18 April 2022
- Original description
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modality (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging and multicenter study, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF in multicenter population.Read full original descriptionShow less
Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction- a Multicenter Study.
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modality (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging and multicenter study, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF in multicenter population.
Inclusion: left ventricular ejection fraction (LVEF)≥50%；; N-terminal pro-b type natriuretic peptide (NT-proBNP)>220pg/ml or b type natriuretic peptide (BNP) >80 pg/ml; symptoms and syndromes of heart failure; At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
Exclusion: Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ; Severe arrhythmia; Severe primary cardiac valvular disease; Restrictive pericardial disease; Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc; Refuse to participate in the study.